- Home
- HGTY vs GPCR Comparison
HGTY vs GPCR Comparison
Compare HGTY & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- GPCR
- Stock Information
- Founded
- HGTY 1984
- GPCR 2016
- Country
- HGTY United States
- GPCR United States
- Employees
- HGTY N/A
- GPCR N/A
- Industry
- HGTY Specialty Insurers
- GPCR
- Sector
- HGTY Finance
- GPCR
- Exchange
- HGTY Nasdaq
- GPCR Nasdaq
- Market Cap
- HGTY 1.1B
- GPCR 1.2B
- IPO Year
- HGTY N/A
- GPCR 2023
- Fundamental
- Price
- HGTY $13.64
- GPCR $37.16
- Analyst Decision
- HGTY Hold
- GPCR Strong Buy
- Analyst Count
- HGTY 7
- GPCR 8
- Target Price
- HGTY $13.83
- GPCR $69.57
- AVG Volume (30 Days)
- HGTY 135.8K
- GPCR 873.1K
- Earning Date
- HGTY 11-04-2025
- GPCR 11-06-2025
- Dividend Yield
- HGTY N/A
- GPCR N/A
- EPS Growth
- HGTY 241.11
- GPCR N/A
- EPS
- HGTY 0.36
- GPCR N/A
- Revenue
- HGTY $1,360,017,000.00
- GPCR N/A
- Revenue This Year
- HGTY $16.08
- GPCR N/A
- Revenue Next Year
- HGTY N/A
- GPCR N/A
- P/E Ratio
- HGTY $37.43
- GPCR N/A
- Revenue Growth
- HGTY 17.92
- GPCR N/A
- 52 Week Low
- HGTY $8.03
- GPCR $13.22
- 52 Week High
- HGTY $13.80
- GPCR $38.48
- Technical
- Relative Strength Index (RSI)
- HGTY 74.14
- GPCR 67.32
- Support Level
- HGTY $10.98
- GPCR $30.70
- Resistance Level
- HGTY $13.80
- GPCR $34.50
- Average True Range (ATR)
- HGTY 0.54
- GPCR 1.89
- MACD
- HGTY 0.30
- GPCR 0.35
- Stochastic Oscillator
- HGTY 96.76
- GPCR 93.58
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.